THE RELATIONSHIP BETWEEN VITAMIN D DEFICIENCY AND THE SEVERITY OF COVID-19
DOI:
https://doi.org/10.53555/nnmhs.v9i6.1733Keywords:
COVID-19, Inflammation, Vitamin D, Severity, DeficiencyAbstract
The global health issue known as the COVID-19 pandemic, resulting from the SARS-CoV-2 virus, has prompted extensive research into factors affecting the severity of the disease. Among these factors, the connection between vitamin D levels and the outcomes of COVID-19 has become an increasingly intriguing field of study.
Vitamin D is a fat-soluble vitamin renowned for its importance in bone health and immune system regulation. According to the latest studies, inadequate levels of vitamin D might be linked to a higher susceptibility to various respiratory infections. As a result, researchers are investigating the potential impact of vitamin D on the severity of COVID-19.
Multiple observational investigations have found a link among a lack of vitamin D and a higher vulnerability to respiratory infections such as COVID-19. Some studies have revealed that individuals with inadequate vitamin D levels had more severe COVID-19 symptoms, greater rates of admission to the hospital, and a greater mortality rate than those with adequate vitamin D levels. Vitamin D is thought to help regulate the immune response by influencing both the adaptive as well as the innate immune systems. Deficiency may affect immunological function, resulting in an altered antiviral response and increased inflammation, which may contribute to the development of COVID-19.
It is crucial to emphasize, however, that the existing research on the connection with insufficient vitamin D levels and the severity of COVID-19 are continuously evolving, with contradicting findings reported. There are significant constraints to the extant research, particularly differences in study methodologies, sample sizes, also populations investigated. Furthermore, it remains uncertain whether there is a cause-and-effect relationship between vitamin D deficiency and COVID-19 severity, as the observed relationships might be impacted by other confounding variables. Given vitamin D's possible involvement in immune function and the existing data linking it to COVID-19 severity, further well-designed research, particularly randomized controlled trials, are needed to demonstrate a causal relationship
References
Argano, C., Mallaci Bocchio, R., Natoli, G., Scibetta, S., Lo Monaco, M. and Corrao, S., 2023. Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. Pharmaceuticals, 16(1), p.130.
Gallo G., Calvez V., Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press. Cardiovasc. Prev. 2022;29:115–123. doi: 10.1007/s40292-022-00506-9
Nielsen, N.M., Junker, T.G., Boelt, S.G., Cohen, A.S., Munger, K.L., Stenager, E., Ascherio, A., Boding, L. and Hviid, A., 2022. Vitamin D status and severity of COVID-19. Scientific Reports, 12(1), p.19823.
Meltzer, D. O. et al. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw. Open. 3(9), e2019722. https://doi.org/10.1001/jamanetworkopen.2020.19722 (2020)
Murai I.H., Fernandes A.L., Sales L.P., Pinto A.J., Goessler K.F., Duran C.S.C., Silva C.B.R., Franco A.S., Macedo M.B., Dalmolin H.H.H., et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021;325:1053–1060. doi:
1001/jama.2020.26848.
Karcioglu Batur, L. & Hekim, N. Te role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate. J. Med. Virol. 93(3), 1409–1413 (2021).
AlSafar H, Grant WB, Hijazi R, Uddin M, Alkaabi N, Tay G, et al. COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents. Nutrients. 2021 May;13(5).
D’Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients. 2020;12(5):1359.
Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25‐hydroxyvitamin D (25 [OH] D) levels in patients hospitalized with COVID‐19 are associated with greater disease severity. Clin Endocrinol (Oxf). 2020;93(4):508.
Carpagnano GE, Di Lecce V, Quaranta VN, Zito A, Buonamico E, Capozza E, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J Endocrinol Invest. 2021;44(4):765–71.
Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar;325(11):1053–60.
Sabico S, Enani MA, Sheshah E, Aljohani NJ, Aldisi DA, Alotaibi NH, et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial. Nutrients. 2021 Jun;13(7).
Saponaro F, Franzini M, Okoye C, Antognoli R, Campi B, Scalese M, et al. Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19? Front Immunol. 2021;12:745713.
Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor κB activation by interacting with IκB kinase β protein. J Biol Chem. 2013;288(27):19450–8.
Wang T-T, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12.
Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18:153–65.
Lanham New SA, Webb AR, Cashman KD, et al. Vitamin D and SARS-CoV-2 virus/COVID-19 disease. BMJ Nutr Prev Heal. 2020;1–5.
Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12:1–19.
Jolliffe DA, Greenberg L, Hooper RL, Mathyssen C, Rafiq R, de Jongh RT, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019 Apr;74(4):337–45.
Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012;156(2):105–14.
Leikina E, Delanoe-Ayari H, Melikov K, Cho M-S, Chen A, Waring AJ, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol. 2005;6(10):995–1001.
Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta (BBA)-Biomembranes. 2006;1758(9):1408–25.
Mirzadeh M; Khedmat L. Pregnant women in the exposure to COVID-19 infection outbreak: the unseen risk factors and preventive healthcare patterns. J Matern Neonatal Med. 2020;
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
